Fabienne ORY

https://tonic.inserm.fr/wp-content/uploads/2019/09/equipe-femme-defaut-150x150.jpg

Travaille sur

Abstracts rédigés ou co-rédigés

> Étude des dimensions de personnalité du TCI chez des patients parkinsoniens fluctuants
Mathilde Boussac ; Christophe Arbus ; Olivier Colin ; Chloé Laurencin ; Alexandre Eusebio ; Elodie Hainque; Jean Christophe Corvol ; Nathalie Versace ; Olivier Rascol; Vanessa Rousseau ; Estelle Harroch ; Fabienne Ory Magne ; Margherita Fabbri ; Caroline Moreau ; Anne Sophie Rolland ; Béchir Jarraya ; David Maltête; Sophie Drapier ; Ana Raquel Marques ; Nicolas Auzou ; Thomas Wirth ; Mylène Meyer ; Bruno Giordana ; Mélissa Tir ; Tiphaine Rouaud ; David Devos ; Christine Brefel Courbon for the PREDISTIM study group
JNLF 2022 (Journées de Neurologie de Langue Française) :12 au 15 avril 2022 à Strasbourg.
> The Association of Personality Dimensions with Quality of Life in Parkinson’s disease patients with motor fluctuations.
Boussac M, Arbus C, Dupouy J, et al.
EAN (European Academy of Neurology) Congress Virtual 2020

Publications rédigées ou co-rédigées

> 48- Oxycodone or Higher Dose of Levodopa for the Treatment of Parkinsonian Central Pain: OXYDOPA Trial.
Brefel-Courbon C, Harroch E, Marques A, Devos D, Thalamas C, Rousseau V, Ory-Magne F, Fabbri M, Maltête D, Rouaud T, Drapier S, Tir M, Thobois S, Salhi H, Corvol JC, Castelnovo G, Lagha-Boukbiza O, Fluchère F, Frismand S, Ansquer S, Sommet A, Rascol O.
Mov Disord. 2024 Jun 8. doi: 10.1002/mds.29878.
> 47- Personality and quality-of-life improvement after apomorphine infusion in Parkinson’s disease.
Boussac M, Harroch E, Barthelemy C, Ory-Magne F, Leung C, Fabbri M, Arbus C, Brefel-Courbon C.
Brain Commun. 2024 May 24;6(3):fcae181. doi: 10.1093/braincomms/fcae181.
> 28- Amantadine use in the French prospective NS-Park cohort.
Fabbri M, Rousseau V, Corvol JC, Sommet A, Tubach F, De Rycke Y, Bertille N, Selvarasa Y, Carvalho S, Chaigneau V, Brefel-Courbon C, Ory-Magne F, Tessier S, Tir M, Bereau M, Meissner WG, Thiriez C, Marques A, Remy P, Schneider V, Moro E, Defebvre L, Houeto JL, Prange S, Eusebio A, Geny C, Frismand S, Damier P, Reuther CG, Castelnovo G, Benatru I, De Maindreville AD, Drapier S, Maltête D, Lagha-Boukbiza O, Rascol O; French N. S.-Park network.
J Neural Transm (Vienna). 2024 Apr 5. doi: 10.1007/s00702-024-02772-4.
> 25- Trial of Lixisenatide in Early Parkinson’s Disease.
Meissner WG, Remy P, Giordana C, Maltête D, Derkinderen P, Houéto JL, Anheim M, Benatru I, Boraud T, Brefel-Courbon C, Carrière N, Catala H, Colin O, Corvol JC, Damier P, Dellapina E, Devos D, Drapier S, Fabbri M, Ferrier V, Foubert-Samier A, Frismand-Kryloff S, Georget A, Germain C, Grimaldi S, Hardy C, Hopes L, Krystkowiak P, Laurens B, Lefaucheur R, Mariani LL, Marques A, Marse C, Ory-Magne F, Rigalleau V, Salhi H, Saubion A, Stott SRW, Thalamas C, Thiriez C, Tir M, Wyse RK, Benard A, Rascol O; LIXIPARK Study Group.
N Engl J Med. 2024 Apr 4;390(13):1176-1185. doi: 10.1056/NEJMoa2312323.
> 15- Clinical and imaging « red flags » for the diagnosis of multiple system atrophy lookalikes.
Gallo S, Ory-Magne F, Le-Traon AP, Rascol O, Debs R, Leung C, Fabbri M.
Parkinsonism Relat Disord. 2023 Mar 20:105372. doi: 10.1016/j.parkreldis.2023.105372.
> 82- Challenging diagnosis and treatment decision of a long-history autoantibody-negative autoimmune encephalitis.
Calvat P, Leung C, Bost C, Fortenfant F, Simonetta-Moreau M, Pariente J, Rafiq M, Brefel-Courbon C, Rascol O, Fabbri M, Ory-Magne F.
Parkinsonism Relat Disord. 2022 Dec 7:105232. doi: 10.1016/j.parkreldis.2022.105232.
> 81- Results of a Randomized Clinical Trial of Speech after Early Neurostimulation in Parkinson’s Disease.
into S, Nebel A, Rau J, Espesser R, Maillochon P, Niebuhr O, Krack P, Witjas T, Ghio A, Cuartero MC, Timmermann L, Schnitzler A, Hesekamp H, Meier N, Müllner J, Hälbig TD, Möller B, Paschen S, Paschen L, Volkmann J, Barbe MT, Fink GR, Becker J, Reker P, Kühn AA, Schneider GH, Fraix V, Seigneuret E, Kistner A, Rascol O, Brefel-Courbon C, Ory-Magne F, Hartmann CJ, Wojtecki L, Fradet A, Maltête D, Damier P, Le Dily S, Sixel-Döring F, Benecke P, Weiss D, Wächter T, Pinsker MO, Régis J, Thobois S, Polo G, Houeto JL, Hartmann A, Knudsen K, Vidailhet M, Schüpbach M, Deuschl G; EARLYSTIM Study Group.
Mov Disord. 2022 Dec 3. doi: 10.1002/mds.29282.
> 80- Trial of Deferiprone in Parkinson’s Disease.
Devos D, Labreuche J, Rascol O, Corvol JC, Duhamel A, Guyon Delannoy P, Poewe W, Compta Y, Pavese N, Růžička E, Dušek P, Post B, Bloem BR, Berg D, Maetzler W, Otto M, Habert MO, Lehericy S, Ferreira J, Dodel R, Tranchant C, Eusebio A, Thobois S, Marques AR, Meissner WG, Ory-Magne F, Walter U, de Bie RMA, Gago M, Vilas D, Kulisevsky J, Januario C, Coelho MVS, Behnke S, Worth P, Seppi K, Ouk T, Potey C, Leclercq C, Viard R, Kuchcinski G, Lopes R, Pruvo JP, Pigny P, Garçon G, Simonin O, Carpentier J, Rolland AS, Nyholm D, Scherfler C, Mangin JF, Chupin M, Bordet R, Dexter DT, Fradette C, Spino M, Tricta F, Ayton S, Bush AI, Devedjian JC, Duce JA, Cabantchik I, Defebvre L, Deplanque D, Moreau C; FAIRPARK-II Study Group.
N Engl J Med. 2022 Dec 1;387(22):2045-2055. doi: 10.1056/NEJMoa2209254.
> 85- Personality Related to Quality-of-Life Improvement After Deep Brain Stimulation in Parkinson’s Disease (PSYCHO-STIM II).
Boussac M, Arbus C, Klinger H, Eusebio A, Hainque E, Christophe Corvol J, Rascol O, Rousseau V, Harroch E, d’Apollonia CS, Croiset A, Ory-Magne F, De Barros A, Fabbri M, Moreau C, Rolland AS, Benatru I, Anheim M, Marques AR, Maltête D, Drapier S, Jarraya B, Hubsch C, Guehl D, Meyer M, Rouaud T, Giordana B, Tir M, Devos D, Brefel-Courbon C; PREDISTIM study group.
J Parkinsons Dis. 2021 Dec 7. doi: 10.3233/JPD-212883.
> 42- A French survey on the lockdown consequences of COVID-19 pandemic in Parkinson’s disease. The ERCOPARK study.
Fabbri M, Leung C, Baille G, Béreau M, Brefel Courbon C, Castelnovo G, Carriere N, Damier P, Defebvre L, Doe de Maindreville A, Fluchere F, Fuzzatti M, Grabli D, Maltete D, Rousseau V, Sommet A A, Thalamas C, Thiriez C, Rascol O, Ory-Magne F.
Parkinsonism Relat Disord. 2021 Jul 13;89:128-133. doi: 10.1016/j.parkreldis.2021.07.013.
> 41- A diagnosis of progressive myoclonic ataxia guided by blood biomarkers.
Dubot P, Rafiq M, Curot J, Simonetta-Moreau M, Sabourdy F, Pettazzoni M, Froissart R, Levade T, Ory-Magne F.
Parkinsonism Relat Disord. 2021 Jul 10:S1353-8020(21)00247-9. doi: 10.1016/j.parkreldis.2021.06.027.
> 31- Body mass index variations in patients with Parkinson’s disease treated with levodopa-carbidopa intestinal gel infusion: A case control study versus standard of care and subthalamic nucleus deep brain stimulation.
Fernández-Rodríguez B, Dupouy J, Harroch E, Fabre-Delcros MH, Barthélémy C, Loubière P, Barange K, Brefel-Courbon C, Rascol O, Ory-Magne F.
Rev Neurol (Paris). 2021 Jun 18:S0035-3787(21)00562-2. doi: 10.1016/j.neurol.2020.11.017.
> 13- Expanding the clinical spectrum of STIP1 homology and U-box containing protein 1-associated ataxia.
Ravel JM, Benkirane M, Calmels N, Marelli C, Ory-Magne F, Ewenczyk C, Halleb Y, Tison F, Lecocq C, Pische G, Casenave P, Chaussenot A, Frismand S, Tyvaert L, Larrieu L, Pointaux M, Drouot N, Bossenmeyer-Pourié C, Oussalah A, Guéant JL, Leheup B, Bonnet C, Anheim M, Tranchant C, Lambert L, Chelly J, Koenig M, Renaud M.
<a
Voir la publication
J Neurol. 2021 Jan 8. doi: 10.1007/s00415-020-10348-x.
> 2- Personality dimensions of patients can change during the course of parkinson’s disease.
Boussac M, Arbus C, Dupouy J, Harroch E, Rousseau V, Croiset A, Ory-Magne F, Rascol O, Moreau C, Rolland AS, Maltête D, Rouaud T, Meyer M, Drapier S, Giordana B, Anheim M, Hainque E, Jarraya B, Benatru I, Auzou N, Belamri L, Tir M, Marques AR, Thobois S, Eusebio A, Corvol JC, Devos D, Brefel-Courbon C; PREDI-STIM study group.
Voir la publication
PLoS One. 2021 Jan 7;16(1):e0245142. doi: 10.1371/journal.pone.0245142.
> 32- Personality Dimensions Are Associated with Quality of Life in Fluctuating Parkinson’s Disease Patients (PSYCHO-STIM).
Boussac M, Arbus C, Dupouy J, Harroch E, Rousseau V, Ory-Magne F, Rascol O, Moreau C, Maltête D, Rouaud T, Meyer M, Houvenaghel JF, Marsé C, Tranchant C, Hainque E, Jarraya B, Ansquer S, Bonnet M, Belamri L, Tir M, Marques AR, Danaila T, Eusebio A, Devos D, Brefel-Courbon C; PREDI-STIM study group.
Voir la publication
J Parkinsons Dis. 2020 May 16. doi: 10.3233/JPD-191903.
> 54- Drug-induced parkinsonism
Ory-Magne F.
Voir la publication
Rev Prat. 2020 May;70(5):475-478.
> 29- Repetitive transcranial magnetic stimulation for functional tremor: A randomized, double-blind, controlled study.
Taib S, Ory-Magne F, Brefel-Courbon C, Moreau Y, Thalamas C, Arbus C, Simonetta-Moreau M.
Mov Disord. 2019 Jun 10. doi: 10.1002/mds.27727.
> 63- Dopamine transporter imaging for the diagnosis of multiple system atrophy cerebellar type.
Vergnet S, Hives F, Foubert-Samier A, Payoux P, Fernandez P, Meyer M, Dupouy J, Brefel-Courbon C, Ory-Magne F, Rascol O, Tison F, Pavy-Le Traon A, Meissner WG.
Voir la publication
Parkinsonism Relat Disord. 2019 Jun;63:199-203. doi: 10.1016/j.parkreldis.2019.02.006. Epub 2019 Feb 5.
> 57- Quality of life predicts outcome of deep brain stimulation in early Parkinson disease.
Schuepbach WMM, Tonder L, Schnitzler A, Krack P, Rau J, Hartmann A, Hälbig TD, Pineau F, Falk A, Paschen L, Paschen S, Volkmann J, Dafsari HS, Barbe MT, Fink GR, Kühn A, Kupsch A, Schneider GH, Seigneuret E, Fraix V, Kistner A, Chaynes PP, Ory-Magne F, Brefel-Courbon C, Vesper J, Wojtecki L, Derrey S, Maltête D, Damier P, Derkinderen P, Sixel-Döring F, Trenkwalder C, Gharabaghi A, Wächter T, Weiss D, Pinsker MO, Regis JM, Witjas T, Thobois S, Mertens P, Knudsen K, Schade-Brittinger C, Houeto JL, Agid Y, Vidailhet M, Timmermann L, Deuschl G; EARLYSTIM study group.
Voir la publication
Neurology. 2019 Mar 5;92(10):e1109-e1120. doi: 10.1212/WNL.0000000000007037. Epub 2019 Feb 8. Erratum in: Neurology. 2019 Jun 11;92(24):1166.
> 69- Repetitive transcranial magnetic stimulation for functional tremor: A randomized, double-blind, controlled study.
Taib S, Ory-Magne F, Brefel-Courbon C, Moreau Y, Thalamas C, Arbus C, Simonetta-Moreau M.
Voir la publication
Mov Disord. 2019 Aug;34(8):1210-1219. DOI:10.1002/mds.27727
> 7- Quality of life predicts outcome of deep brain stimulation in early Parkinson disease.
Schuepbach WMM, Tonder L, Schnitzler A, Krack P, Rau J, Hartmann A, Hälbig T, Pineau F, Falk A, Paschen L, Paschen S, Volkmann J, Dafsari HS, Barbe MT, Fink GR, Kühn A, Kupsch A, Schneider GH, Seigneuret E, Fraix V, Kistner A, Chaynes PP, Ory-Magne F, Brefel-Courbon C, Vesper J, Wojtecki L, Derrey S, Maltête D, Damier P, Derkinderen P, Sixel-Döring F, Trenkwalder C, Gharabaghi A, Wächter T, Weiss D, Pinsker MO, Regis JM, Witjas T, Thobois S, Mertens P, Knudsen K, Schade-Brittinger C, Houeto JL, Agid Y, Vidailhet M, Timmermann L, Deuschl G; EARLYSTIM study group.
Neurology. 2019 Feb 8. pii: 10.1212/WNL.0000000000007037. doi: 10.1212/WNL.0000000000007037.
> 6- Dopaminergic denervation using [123I]-FPCIT and pain in Parkinson’s disease: a correlation study.
Dellapina E, Pellaprat J, Adel D, Llido J, Harroch E, Martini JB, Kas A, Salabert AS, Ory-Magne F, Payoux P, Brefel-Courbon C.
J Neural Transm (Vienna). 2019 Jan 31. doi: 10.1007/s00702-019-01974-5.
> 28- Cognitive complaint in early Parkinson’s disease: A pilot study.
Dupouy J, Ory-Magne F, Mekies C, Rousseau V, Puel M, Rerat K, Pariente J, Brefel-Courbon C; PARKMIP group.
Acta Neurol Scand. 2018 Jan;137(1):59-66. doi: 10.1111/ane.12808. Epub 2017 Aug 22.
> 66- Abnormal pain perception in patients with Multiple System Atrophy.
Ory-Magne F, Pellaprat J, Harroch E, Galitzsky M, Rousseau V, Pavy-Le Traon A, Rascol O, Gerdelat A, Brefel-Courbon C.
Parkinsonism Relat Disord. 2017 Dec 8. pii: S1353-8020(17)30827-1. doi: 10.1016/j.parkreldis.2017.12.001.
> 41- Cognitive complaint in early Parkinson’s disease: A pilot study.
Dupouy J, Ory-Magne F, Mekies C, Rousseau V, Puel M, Rerat K, Pariente J, Brefel-Courbon C; PARKMIP group.
Acta Neurol Scand. 2017 Aug 22. doi: 10.1111/ane.12808.
> 45- Parkinson’s patients can rely on perspective cues to perceive 3D space.
Séverac Cauquil A, Ory-Magne F, Jardiné V, Galitzky M, Rosito M, Brefel-Courbon C, Celebrini S.
Brain Res. 2017 May 15;1663:161-165. doi: 10.1016/j.brainres.2017.03.017. Epub 2017 Mar 19.
> 14- A longitudinal follow-up study of the quantiﬁcation of dopamine transporters with 123I-Ioﬂupane (DaTscan)
H. Fayolle, P. Gantet, A.S. Salabert, J. Delrieu, C. Brefel-Courbon, F. Ory-Magne, T. Voisin, P. Payoux
Médecine Nucléaire 41 (2017) 36-41
> 56- Clinical Impact and Cost-Effectiveness of an Education Program for PD Patients: A Randomized Controlled Trial.
Canivet C, Costa N, Ory-Magne F, Arcari C, Mohara C, Pourcel L, Derumeaux H, Bérard E, Bourrel R, Molinier L, Brefel-Courbon C.
PLoS One. 2016 Sep 29;11(9):e0162646. doi: 10.1371/journal.pone.0162646.
> 51- Case report of Lewy body disease mimicking Creutzfeldt-Jakob disease in a 44-year-old man.
Saint-Aubert L, Pariente J, Dumas H, Payoux P, Brandel JP, Puel M, Vital A, Guedj E, Lesage S, Peoc’h K, Brefel Courbon C, Ory Magne F.
BMC Neurol. 2016 Jul 30;16:122. doi: 10.1186/s12883-016-0643-y.
> Deep brain stimulation of the subthalamic nucleus improves pain in Parkinson’s disease.
Pellaprat J, Ory-Magne F, Canivet C, Simonetta-Moreau M, Lotterie JA, Radji F, Arbus C, Gerdelat A, Chaynes P, Brefel-Courbon C.
Parkinsonism Relat Disord. 2014 Jun;20(6):662-4. doi: 10.1016/j.parkreldis.2014.03.011.
> [A therapeutic educational program in Parkinson’s disease: ETPARK].
Ory Magne F, Arcari C, Canivet C, Sarrail M, Fabre MH, Mohara C, Brefel Courbon C.
Rev Neurol (Paris). 2014 Feb;170(2):128-33. doi: 10.1016/j.neurol.2013.08.007. French.
> Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.
Ory-Magne F, Corvol JC, Azulay JP, Bonnet AM, Brefel-Courbon C, Damier P, Dellapina E, Destée A, Durif F, Galitzky M, Lebouvier T, Meissner W, Thalamas C, Tison F, Salis A, Sommet A, Viallet F, Vidailhet M, Rascol O; NS-Park CIC Network..
Neurology. 2014 Jan 28;82(4):300-7. doi: 10.1212/WNL.0000000000000050.